Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674232 | SCV000799534 | uncertain significance | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2018-04-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001300495 | SCV001489638 | likely pathogenic | not provided | 2024-01-30 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 78 of the USH2A protein (p.Phe78Val). This variant is present in population databases (rs775094277, gnomAD 0.002%). This missense change has been observed in individuals with clinical features of Usher syndrome (PMID: 27460420, 33576794; Invitae). ClinVar contains an entry for this variant (Variation ID: 558020). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt USH2A protein function with a negative predictive value of 95%. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Fulgent Genetics, |
RCV000674232 | SCV002781147 | uncertain significance | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2021-07-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003459644 | SCV004208400 | likely pathogenic | Retinitis pigmentosa 39 | 2024-03-02 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001830462 | SCV002094034 | uncertain significance | Usher syndrome type 2A | 2020-01-16 | no assertion criteria provided | clinical testing |